Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Isunakinra - Sesen Bio

Next Previous
Drug Profile

Isunakinra - Sesen Bio

Alternative Names: EBI 005 1; EBI 005 2; EBI-005

Latest Information Update: 06 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eleven Biotherapeutics
  • Developer Buzzard Pharmaceuticals; Eleven Biotherapeutics
  • Class Anti-inflammatories; Eye disorder therapies; Immunotherapies; Peptides; Proteins; Recombinant proteins
  • Mechanism of Action Interleukin 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • Discontinued Allergic conjunctivitis; Dry eyes

Most Recent Events

  • 02 Jun 2023 Interim pharmacokinetics, adverse events and efficacy data from a phase-I/II trial in Solid tumours presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023) (NCT04121442)
  • 29 Dec 2022 Isunakinra is still in phase I/IIs trial for solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (unspecified route) (NCT04121442)
  • 29 Dec 2022 Isunakinra is still in phase I/IIs trial for solid tumours (Metastatic disease, Late-stage disease, Second-line therapy or greater, Inoperable/Unresectable, Combination therapy) in USA (unspecified route) (NCT04121442)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top